The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

por George, Suraj Konnath, Vishwamitra, Deeksha, Manshouri, Roxsan, Shi, Ping, Amin, Hesham M.
Publicado 2014

Type I insulin-like growth factor receptor signaling in hematological malignancies

por Vishwamitra, Deeksha, George, Suraj Konnath, Shi, Ping, Kaseb, Ahmed O., Amin, Hesham M.
Publicado 2016

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK (+) T‐cell lymphoma

por Shi, Wenyu, George, Suraj Konnath, George, Bhawana, Curry, Choladda V., Murzabdillaeva, Albina, Alkan, Serhan, Amin, Hesham M.
Publicado 2017

Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms

por Yang, Lujun, Zhang, Shuangfeng, George, Suraj Konnath, Teng, Rong, You, Xuefen, Xu, Mengqi, Liu, Hong, Sun, Xiaoping, Amin, Hesham M., Shi, Wenyu
Publicado 2015

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma

por George, Bhawana, George, Suraj Konnath, Shi, Wenyu, Haque, Abedul, Shi, Ping, Eskandari, Ghazaleh, Axelson, Magnus, Larsson, Olle, Kaseb, Ahmed O., Amin, Hesham M.
Publicado 2023

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma

por George, Bhawana, George, Suraj Konnath, Shi, Wenyu, Haque, Abedul, Shi, Ping, Eskandari, Ghazaleh, Axelson, Magnus, Larsson, Olle, Kaseb, Ahmed O., Amin, Hesham M.
Publicado 2019